P514Reducing intensive glycaemic management among older people with Type 2 diabetes prescribed sulphonylurea (SU) or insulin therapiesC HAMBLING1,2, S Seidu1 and K Khunti11Diabetes Research Centre, University of Leicester, Leicester, UK, 2West Norfolk Clinical Commissioning Group, King's Lynn, UKRefer to Oral number A5P515Early‐onset Type 2 diabetes is associated with higher risk of mortality: An analysis of the National Diabetes AuditN HOLMAN1, N Sattar1, S Wild2, K Khunti3 and B Young41Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK, 2Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK, 3Diabetes Research Centre, University of Leicester, Leicester, UK, 4National Diabetes Audit, Diabetes UK, London, UKRefer to Oral number A19P516Fixed ratio combination insulin degludec/liraglutide (IDegLira) vs basal bolus therapy (insulin glargine‐U100 plus insulin aspart) for the management of Type 2 diabetes: A short‐term cost‐effectiveness analysis in the UK settingR DRUMMOND1,2, SJP Malkin3, M Du Preez4, XY Lee5 and B Hunt31Diabetes and Endocrinology, Glasgow Royal Infirmary, Glasgow, UK, 2School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK, 3Health Economics and Communications, Ossian Health Economics and Communications, Basel, Switzerland, 4EU Health Economics and Outcomes Research, Novo Nordisk Ltd., Gatwick, UK, 5Global Market Access – HEOR Insulin, Novo
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera